Find investors
← Back to all investors
Sergey Sherman
ResearchedAngel Investors

Sergey Sherman

Managing Director - Investments

Angel InvestorsSeed Round
Pitch Sergey

Get their honest, personalized take on your startup.

Sign in to pitch Sergey

At a glance

Full Name
Sergey Sherman
Title
Managing Director
Firm
Industrial Development Funding LLC (IDF)
Firm Type
SEC-registered investment adviser; infrastructure private credit / bespoke capital-solutions platform
Investment Stage
Growth, deployment, construction, project finance, private credit; formerly growth-stage private equity and private credit at Tuatara Capital
Check Size
IDF public deal examples range from $80 million small-ticket finance vehicles to $1.7 billion project investments
Target Company Profile
Industrial companies and infrastructure projects needing off-balance-sheet, risk-share, product sales, product development, construction, or deployment financing
Sector Focus
Energy, digital infrastructure, transportation, industrials; formerly legal cannabis, cannabinoid biotechnology, cannabis technology, and regulated-market software
Geographic Focus
United States and global industrial counterparties; IDF lists offices in Miami Beach, New York, and Gurgaon, India
Location
New York City Metropolitan Area; IDF headquarters in Miami Beach, Florida, with a New York branch office

Background

Sergey Sherman is a Managing Director with Industrial Development Funding LLC, where he is part of an investment team focused on private credit and bespoke financing for energy, digital infrastructure, transportation, and industrial sectors. IDF describes itself as an SEC-registered investment adviser that manages capital for Qualified Institutional Buyers and provides capital solutions to large industrial companies selling existing products or bringing new products to market.

Before joining IDF, Sherman was Managing Director/Partner, Private Equity and Co-Head of Private Credit Strategies at Tuatara Capital LP. Tuatara was founded in 2014 as an alternative investment manager focused on the legal cannabis industry and later described itself as making long-term investments into market-leading, growth-stage companies. Sherman joined Tuatara in 2019 as Managing Director on the investment team, overseeing origination, structuring, due diligence, financing, and portfolio management.

Earlier in his career, Sherman was a Managing Director at Societe Generale, where he led U.S. coverage of middle-market private equity firms. He previously worked in the Financial Sponsors Groups at RBC Capital Markets and J.P. Morgan, and before investment banking he worked in business development and M&A at GE Capital. His IDF biography states that he has over 20 years of investment banking and finance experience and played leadership roles in more than $50 billion of M&A, debt, and equity capital markets transactions.

Sherman began his career as a nuclear submarine officer in the U.S. Navy. He holds a B.S. in Electrical Engineering from Carnegie Mellon University and an MBA from The George Washington University. He has also served as a board member or observer for SpringBig, Hana, Hound Labs, Willow Biosciences, Caliva, CT Pharmaceutical Solutions, and Enlighten Technologies.

Investment Thesis & Focus

  • IDF’s current focus is not seed-stage angel investing. The firm targets private credit and project-finance structures for companies and projects in energy, digital infrastructure, transportation, and industrial sectors.
  • IDF states that its proprietary funding solutions help large industrial companies “sell existing products or introduce new products to the marketplace.”
  • IDF’s public materials emphasize “bespoke capital solutions” across digital infrastructure, power, transportation, and industrial sectors.
  • Sherman’s background suggests a bias toward structured transactions: origination, transaction structuring, diligence, financing, leveraged finance, private equity, and credit.
  • At Tuatara, Sherman said he was joining to focus on “making investments in the high-growth legal cannabis industry” and to help “entrepreneurial and innovative cannabis companies” with banking and transaction experience.
  • Tuatara’s stated investment philosophy centered on partnership with management teams, providing strategic, financial, and operational support to navigate regulatory and commercial frameworks.

Notable Investments

  • Bloom Energy / Nebius AI infrastructure: IDF and Oaktree announced a $1.7 billion project investment in July 2026 to deploy Bloom Energy fuel cells for Nebius AI cloud infrastructure; IDF is the lead developer.
  • Bloom Energy fuel-cell portfolios: IDF announced in March 2026 that it funded more than $650 million of Bloom Energy fuel-cell energy servers across three portfolios serving commercial, industrial, and data-center customers.
  • Bloom Energy / HPS / IDF: In December 2024, IDF collaborated with Bloom Energy and HPS Investment Partners on a $125 million investment acquiring 19 MW of Bloom Energy Servers.
  • Lambda Labs: IDF collaborated with Lambda Labs and Macquarie Group on an up-to-$500 million GPU-backed facility announced in March 2024 to expand AI cloud infrastructure.
  • SpringBig: Cannabis loyalty and marketing software platform; Sherman joined the post-SPAC board in 2022, later served as Audit Committee chair, and resigned from the board effective September 4, 2025.
  • Hound Labs: Health technology company developing the HOUND marijuana breathalyzer; Tuatara joined a $20 million September 2021 financing round, and Sherman has been listed as a board member/observer.
  • Demetrix: Biotechnology company producing cannabinoids via fermentation; Tuatara led its $50 million Series A in July 2019.
  • Willow Biosciences: Synthetic biology company focused on ingredients and active pharmaceutical ingredients; Tuatara made strategic investments in 2019 and 2020, and Sherman has been listed as a board member/observer.
  • Enlighten Technologies: Cannabis technology company; Tuatara led an oversubscribed Series B round of more than $6.5 million in June 2019, and Sherman has been listed as a board member/observer.
  • CT Pharmaceutical Solutions: Cannabinoid production company for medical marijuana products; Sherman has been listed as a director/board member.
  • Hana: Cannabis distributor in Arizona; Sherman has been listed as a board member/observer.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.